ASML's $8 Billion Order Meets a Washington Roadblock

A landmark $8 billion order from SK Hynix for its most advanced EUV lithography systems should be a clear signal of ASML Holding NV's enduring dominance. Instead, the Dutch chip equipment giant faces a pivotal week where that strength is being tested by a new political initiative from Washington. Investors are bracing for first-quarter results and management commentary that must reconcile robust demand with escalating geopolitical risks.

The source of the tension is the proposed MATCH Act, introduced in the U.S. Congress on April 2. This bipartisan legislation aims to sever China's access to critical chipmaking tools, explicitly banning the sale and, crucially, the maintenance of immersion deep ultraviolet (DUV) lithography machines. These systems have remained a stable revenue source for ASML even under previous export controls, serving Chinese chipmakers like SMIC, Hua Hong, Huawei, CXMT, and YMTC.

Analysts at Bernstein label the draft "significantly stricter" than prior restrictions. The market reaction was swift, with ASML shares falling 2.6% on the news. While the company and the Dutch government have declined to comment on foreign legislative proposals, the financial implications are being modeled. Ben Barringer of Quilter Cheviot estimates the impact on roughly 5% of total sales, given that older lithography systems contribute 10-15% of revenue, with China accounting for about half of that. A more severe Bank of America scenario, assuming a full ban on immersion tools, projects a potential 14-15% hit to revenue and a 16-17% decline in EBIT.

This political uncertainty arrives just as ASML prepares to report its Q1 2026 figures on Wednesday, April 15. The company had guided for net sales between EUR 8.2 and EUR 8.9 billion, with a gross margin of 51-53%, down from 54% a year ago due to product mix and softer service income. Beyond the headline numbers, analysts will focus on the pace at which ASML converts its massive order backlog—EUR 38.8 billion as of end-2025—into recognized sales. The options market is pricing in a share price move of around five percent on earnings day.

Should investors sell immediately? Or is it worth buying Asml?

The company's guidance for China to contribute approximately 20% of sales in 2026, down from 33% in 2025, was issued before the MATCH Act surfaced. CEO Christophe Fouquet's assessment of whether that forecast still holds will be a key focus during the 15:00 CET investor call with CFO Roger Dassen.

Despite the headwinds, ASML's financial foundations appear solid. The record order from SK Hynix, for delivery through 2027, underscores relentless demand for cutting-edge EUV technology, which now constitutes over half of new bookings. For the full year 2026, management anticipates net sales between EUR 34 and EUR 39 billion.

Shareholder returns continue unabated. The company repurchased approximately 87,956 of its own shares for about EUR 100 million in late March and early April, part of a broader program of up to EUR 12 billion announced in January. Shareholders will vote on a final dividend of EUR 2.70 per share at the Annual General Meeting on April 22, which would bring the total 2025 dividend to EUR 7.50—a 17% year-on-year increase. The payout is scheduled for April 24.

Asml at a turning point? This analysis reveals what investors need to know now.

The AGM will also see the proposed appointment of Marco Pieters as Chief Technology Officer for a four-year term, alongside the reappointment of CFO Roger Dassen and COO Frédéric Schneider-Maunoury.

With the stock up roughly 27% year-to-date and trading well above its 200-day moving average, the coming days will test whether ASML's operational prowess and record order book can outweigh the growing shadow of U.S. policy. The balance between a booming AI-driven chip cycle and tightening geopolitical constraints is now squarely on display.

Ad

Asml Stock: New Analysis - 13 April

Fresh Asml information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Asml analysis...

en | NL0010273215 | ASMLS | boerse | 69137820 |